Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate

10 Mar Launch of Odylia’s Newsletter

Posted at 08:43h in Press Releases by Odylia Media

Atlanta, GA March 10th, 2021 – Odylia is pleased to announce the launch of our newsletter which can be read here. In this edition, we discuss how Odylia is reimagining drug development for rare diseases and our 2020 highlights.  The newsletter will be sent a few times a year, so please sign up for future editions here.

Print page


Latests Posts
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform

    13 May, 2025
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy

    05 May, 2025
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event

    10 April, 2025
Categories
  • Press Releases
  • Uncategorized
Tags
Amgen Prize Board of Directors Comend Concordia Summit February 2025 gene therapy Joy Cavagnaro marketplace MIT Solve nephrocystin-1 nephronophthisis NPHP1 NPHP1 Family Foundation Odylia patient groups PURA purine-rich element-binding protein alpha purine rich rare disease Rare Disease Day Senior-Loken Syndrome SKS Smith Kingsmore Smith Kingsmore Foundation The Collective The Odylia Collective
Services
  • Odylia Pipeline & Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs